News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Biogen, Inc. (Massachusetts) (BGEN) And IDEC Pharmaceuticals Corporation (IDPH) To Make Presentation At Credit Suisse First Boston Healthcare Conference


10/19/2005 5:10:32 PM

CAMBRIDGE, Mass., and SAN DIEGO, Nov. 11 /PRNewswire-FirstCall/ -- Biogen, Inc. and IDEC Pharmaceuticals Corporation announced today that IDEC's Chairman and Chief Executive Officer, William H. Rastetter, Ph.D., and Biogen's Chief Financial Officer, Peter Kellogg, will make a presentation at the Credit Suisse First Boston Healthcare Conference on Thursday, November 13, 2003 at 9:00 a.m. Mountain Time (MT) at The Arizona Biltmore Resort in Phoenix, Arizona.

(Logo: http://www.newscom.com/cgi-bin/prnh/19990824/BIOLOGO )

Assuming the merger between IDEC and Biogen is approved by shareholders at Special Meetings on Wednesday, November 12, held in San Diego and Cambridge, respectively, Mr. Rastetter and Mr. Kellogg would give a presentation about the new Biogen Idec.

The presentation will be webcast live and is accessible by using the link provided in the investor relations section of Biogen's (http://www.biogen.com/) and IDEC's (http://www.idecpharm.com/) websites.

About Biogen

Biogen is the world's oldest independent biotechnology company and a leader in biologics research, development and manufacturing. A pioneer in leading edge research in immunology, neurobiology and oncology, Biogen brings novel therapies to improve patients' lives around the world through its global marketing capabilities.

About IDEC Pharmaceuticals

IDEC is a leader in the discovery, development, and commercialization of targeted immunotherapies for the treatment of cancer and autoimmune diseases. IDEC discovered and developed the first commercially available radioimmunotherapy product (Zevalin(R)) approved in the United States, which is used to treat certain non-Hodgkin's lymphomas. IDEC also discovered and, with co-promotion partner Genentech, Inc., developed the first monoclonal antibody product (Rituxan(R)) approved in the United States for the treatment of cancer. Rituxan is approved in over 70 countries worldwide and is also used to treat various types of non-Hodgkin's lymphomas. IDEC is a San Diego-based, integrated biopharmaceutical company with multiple products in clinical stage development and strategic alliances in a variety of research platforms.

Contact: Rob Jacobson Investor Relations Specialist Biogen, Inc. 617/679-3710

Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/19990824/BIOLOGOAP Archive: http://photoarchive.ap.org/PRN Photo Desk, 888-776-6555 or 212-782-2840 Biogen, Inc.

CONTACT: Rob Jacobson, Investor Relations Specialist of Biogen,+1-617-679-3710


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES